iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer
iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the appointment of Dr. Nils Peter Debus as Chief Business Officer (CBO) to drive the company’s new stage of growth. Dr. Debus is an accomplished life science leader with 27 years of industry experience and an outstanding track record in Business Development & Licensing.
Nils Peter Debus, Ph.D., Chief Business Officer, iOmx Therapeutics
iOmx Therapeutics AG
Dr. Apollon Papadimitriou, CEO of iOmx, said: “Nils brings us significant strategic business expertise with a proven success in building partnerships and executing transformative collaborations and acquisitions. His broad industry experience, will be invaluable as we further grow our global business development activities.”
Dr. Nils Debus, CBO of iOmx, added: “iOmx has made impressive progress in a brief time, leveraging its iOTarg platform to address novel immune checkpoints on myeloid cells and advancing its first novel immune checkpoint inhibitor into the clinic. By identifying novel tumor evasion biology, we will further unlock the immune system's potential to combat cancer and tackle tumors, which currently show resistance to existing immunotherapies. I look forward to working with Apollon and the entire iOmx team to build strong partnerships with pharma to maximize our strategic options. We invite the biopharma community to explore our exciting platform and advanced programs for collaboration opportunities.”
Before joining iOmx Dr. Debus held the CBO position at OSE Immunotherapeutics (Paris, France), a company focusing on innovative treatments for immuno-oncology and autoimmune disorders. At Boehringer Ingelheim (Ingelheim, Germany), he spent nine years in senior BD&L roles with a focus on biosimilars, strategic transactions and alliance management, handling R&D pipeline and commercialization deals, as well as patent negotiations. At Merz Pharmaceuticals (Frankfurt, Germany) he served as VP of BD. He started his BD&L career at Schering AG (now Bayer) in Berlin, Germany. Dr. Debus is a microbiologist by training and holds a PhD in embryonic stem cell research from Humboldt University (Berlin, Germany). In addition, he received training in corporate finance from Duke University (Durham, USA).
Other news from the department people
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.